3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
7
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Lung Neoplasms
2
Hematologic Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Non-small Cell Lung Cancer Metastatic
1
Neoplasms
1
Neoplasm Metastasis
1
Meningioma
1
Melanoma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Glioma
1
Exanthema
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Diarrhea
1
Interventions
Rituximab
45
Cyclophosphamide
34
Doxorubicin
16
fludarabine
14
Prednisone
14
Vincristine
13
Etoposide
13
ibrutinib
10
Mycophenolic Acid
8
Bortezomib
8
Magnetic Resonance Spectroscopy
7
Lenalidomide
7
Cytarabine
7
pembrolizumab
6
Immunotherapy, Adoptive
6
polatuzumab vedotin
5
fludarabine phosphate
5
Whole-Body Irradiation
5
Vorinostat
5
Tacrolimus
5
Specimen Handling
5
CT-P10
5
obinutuzumab
4
ibritumomab tiuxetan
4
Nivolumab
4
Ifosfamide
4
Carmustine
4
Carboplatin
4
Antilymphocyte Serum
4
tafasitamab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Lymphoma, B-Cell
×
capivasertib
×
Clear all
NCT05008055
2024-12-20
CAPITAL
AstraZeneca
Phase 2
Completed
30 enrolled
15 charts